Table 2.

Resveratrol-mediated sensitization of NHL and MM cell lines but not PBMCs to paclitaxel-mediated apoptosis

ControlPaclitaxel (nm)
0.1110
Raji9.51 ± 1.910.3 ± 2.911.3 ± 1.822.6 ± 1.1
Raji + resveratrol9.83 ± 1.423.2 ± 2.6*24.4 ± 3.9*54.3 ± 1.6*
8226/S4.7 ± 0.57.5 ± 0.132.8 ± 0.432.8 ± 0.1
8226/S + resveratrol7.7 ± 0.714.6 ± 3.5NS43.8 ± 1.6*57.8 ± 3.2*
8226/Dox404.4 ± 0.113.9 ± 0.58.5 ± 1.911 ± 2.4
8226/Dox40 + resveratrol5.5 ± 0.46.8 ± 0.4NS8.3 ± 0.1NS10 ± 0.1NS
PBMC8.7 ± 1.3ND9.0 ± 1.69.6 ± 1.1
PBMC + resveratrol8.4 ± 1.1ND10.6 ± 1.5NS9.8 ± 1.9NS
PBMC (LPS)10.2 ± 2.6ND9.6 ± 2.98.7 ± 2.2
PBMC (LPS) + resveratrol11.0 ± 0.8ND17.7 ± 3.6NS14.4 ± 2.7NS
  • Note: Freshly derived PBMCs were either left untreated or treated with LPS (20 ng/ml, 3 days). CD20-expressing PBMCs were at their log phase of growth and along with the tumor cell lines were treated under the conditions explained in the legend of Fig. 2. Thereafter, the cells were harvested, stained with the PI solution, and subjected to DNA fragmentation assay using flow cytometry. The percentage of apoptotic cells is represented as the percentage of hypodiploid cells accumulated at sub-G0 fraction of the cell cycle. The samples were set up in duplicates. Results are represented as means ± SD of two independent experiments. NS, statistically not significant; ND, not determined.

  • * P < 0.05, significant compared with paclitaxel treatment alone.